
aTyr Pharma, Inc. (NASDAQ:ATYR – Free Report) – Equities research analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for shares of aTyr Pharma in a report issued on Friday, November 6th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($23.57) per share for the year, down from their previous estimate of ($15.60). The consensus estimate for aTyr Pharma’s current full-year earnings is ($22.96) per share. HC Wainwright also issued estimates for aTyr Pharma’s Q4 2026 earnings at ($7.51) EPS, FY2027 earnings at ($10.65) EPS and FY2028 earnings at ($10.00) EPS.
A number of other research analysts have also issued reports on ATYR. Royal Bank Of Canada lowered their target price on shares of aTyr Pharma to $6.00 and set a “sector perform” rating on the stock in a research note on Friday, November 6th. Weiss Ratings lowered shares of aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. Freedom Broker cut shares of aTyr Pharma from a “strong-buy” rating to a “hold” rating in a report on Friday, November 6th. Wells Fargo & Company raised their price target on aTyr Pharma from $1.00 to $4.00 and gave the company an “equal weight” rating in a research report on Friday, November 6th. Finally, Wall Street Zen raised aTyr Pharma to a “hold” rating in a research report on Saturday, October 31st. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $5.00.
aTyr Pharma Stock Down 10.4%
NASDAQ ATYR opened at $6.77 on Tuesday. The company has a fifty day simple moving average of $10.88 and a 200 day simple moving average of $23.26. aTyr Pharma has a 1 year low of $4.07 and a 1 year high of $44.40.
aTyr Pharma (NASDAQ:ATYR – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($7.43) EPS for the quarter, missing the consensus estimate of ($4.00) by ($3.43). The business had revenue of $235.23 million during the quarter, compared to the consensus estimate of $2.50 million.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in aTyr Pharma stock. Renaissance Technologies LLC acquired a new stake in aTyr Pharma, Inc. (NASDAQ:ATYR – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 40,522 shares of the company’s stock, valued at approximately $32,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.
About aTyr Pharma
aTyr Pharma, Inc. (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation. aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.
See Also
- Five stocks we like better than aTyr Pharma
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
